MX2022000812A - Metodos de tratamiento de hiperplasia suprarrenal congenita. - Google Patents
Metodos de tratamiento de hiperplasia suprarrenal congenita.Info
- Publication number
- MX2022000812A MX2022000812A MX2022000812A MX2022000812A MX2022000812A MX 2022000812 A MX2022000812 A MX 2022000812A MX 2022000812 A MX2022000812 A MX 2022000812A MX 2022000812 A MX2022000812 A MX 2022000812A MX 2022000812 A MX2022000812 A MX 2022000812A
- Authority
- MX
- Mexico
- Prior art keywords
- treatment
- methods
- adrenal hyperplasia
- congenital adrenal
- cah
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962876176P | 2019-07-19 | 2019-07-19 | |
| US202063047822P | 2020-07-02 | 2020-07-02 | |
| PCT/US2020/042820 WO2021016208A1 (en) | 2019-07-19 | 2020-07-20 | Methods of treating congenital adrenal hyperplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022000812A true MX2022000812A (es) | 2022-02-16 |
Family
ID=74193935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022000812A MX2022000812A (es) | 2019-07-19 | 2020-07-20 | Metodos de tratamiento de hiperplasia suprarrenal congenita. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20220133742A1 (enExample) |
| EP (1) | EP3986416A4 (enExample) |
| JP (1) | JP2022541550A (enExample) |
| KR (1) | KR20220052927A (enExample) |
| CN (1) | CN114423436A (enExample) |
| AU (1) | AU2020318970B2 (enExample) |
| BR (1) | BR112022000956A2 (enExample) |
| CA (1) | CA3147891A1 (enExample) |
| MX (1) | MX2022000812A (enExample) |
| TW (1) | TW202116324A (enExample) |
| WO (1) | WO2021016208A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6585625B2 (ja) | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎皮質過形成の処置のためのcrf1レセプターアンタゴニスト |
| KR20250022913A (ko) | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| CN112423747A (zh) | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| MA54395A (fr) | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
| CN114502162B (zh) | 2019-09-27 | 2025-03-28 | 纽罗克里生物科学有限公司 | Crf受体拮抗剂及使用方法 |
| MX2023001688A (es) * | 2020-08-12 | 2023-02-22 | Spruce Biosciences Inc | Metodos y composiciones para tratar el sindrome de ovario poliquistico. |
| US20240024330A1 (en) * | 2020-08-26 | 2024-01-25 | Neurocrine Biosciences, Inc. | Crf receptor antagonists and methods of use |
| MD20210019A2 (ro) | 2021-04-12 | 2022-10-31 | Максим МАСЮТИН | Metodă de tratament a hiperplaziei suprarenale congenitale, cauzate de deficit de 21-hidroxilază cu debut tardiv prin regimul de glucocorticoizi adaptat individual |
| WO2023091684A1 (en) * | 2021-11-19 | 2023-05-25 | Spruce Biosciences, Inc. | Crystalline composition of tildacerfont and methods of use and preparation thereof |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050085479A1 (en) * | 2003-08-27 | 2005-04-21 | Pharmacia Corporation | Mediated central nervous system compositions of a cyclooxygenase-2 selective inhibitor and a corticotropin releasing factor antagonist for the treatment of ischemic disorders or injury |
| WO2005053796A1 (en) * | 2003-12-02 | 2005-06-16 | B & B Beheer Nv | Use of d4 and 5-ht2a antagonists, inverse agonists or partial agonists |
| CN101516835A (zh) * | 2006-07-19 | 2009-08-26 | 俄亥俄州立大学研究基金会 | 选择性雄激素受体调节剂、它们的类似物和衍生物以及它们的用途 |
| UA96458C2 (ru) * | 2006-09-20 | 2011-11-10 | Эли Лилли Энд Компани | Тиазолпиразолопиримидиновые соединения как антагонисты рецептора crf1 |
| JP2015516979A (ja) * | 2012-04-23 | 2015-06-18 | ホルスボールマッシュマイヤー ニューロケミー ゲーエムベーハーHolsboermaschmeyer Neurochemie Gmbh | Crh過剰活性を有する患者の治療に用いるためのcrhr1アンタゴニスト |
| JP6585625B2 (ja) * | 2014-01-21 | 2019-10-02 | ニューロクライン バイオサイエンシーズ,インコーポレイテッド | 先天性副腎皮質過形成の処置のためのcrf1レセプターアンタゴニスト |
| KR20250022913A (ko) * | 2017-08-14 | 2025-02-17 | 스프루스 바이오사이언시스 인코포레이티드 | 코티코트로핀 방출 인자 수용체 길항제 |
| MX2019015318A (es) * | 2017-08-14 | 2020-07-20 | Spruce Biosciences Inc | Antagonistas del receptor del factor liberador de corticotropina. |
| CN112423747A (zh) * | 2018-04-27 | 2021-02-26 | 云杉生物科学公司 | 用于治疗睾丸肾上腺残余瘤和卵巢肾上腺残余瘤的方法 |
| MA54395A (fr) * | 2018-12-07 | 2022-03-16 | Neurocrine Biosciences Inc | Antagoniste du récepteur crf1, formulations pharmaceutiques et formes solides correspondantes pour le traitement de l'hyperplasie surrénalienne congénitale |
-
2020
- 2020-07-20 TW TW109124484A patent/TW202116324A/zh unknown
- 2020-07-20 CN CN202080065892.7A patent/CN114423436A/zh active Pending
- 2020-07-20 BR BR112022000956A patent/BR112022000956A2/pt unknown
- 2020-07-20 MX MX2022000812A patent/MX2022000812A/es unknown
- 2020-07-20 WO PCT/US2020/042820 patent/WO2021016208A1/en not_active Ceased
- 2020-07-20 EP EP20844541.1A patent/EP3986416A4/en active Pending
- 2020-07-20 CA CA3147891A patent/CA3147891A1/en active Pending
- 2020-07-20 AU AU2020318970A patent/AU2020318970B2/en active Active
- 2020-07-20 KR KR1020227005252A patent/KR20220052927A/ko active Pending
- 2020-07-20 JP JP2022503463A patent/JP2022541550A/ja active Pending
-
2022
- 2022-01-18 US US17/578,149 patent/US20220133742A1/en active Pending
-
2024
- 2024-02-09 US US18/438,060 patent/US20240261300A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021016208A1 (en) | 2021-01-28 |
| CN114423436A (zh) | 2022-04-29 |
| AU2020318970A1 (en) | 2022-03-03 |
| AU2020318970B2 (en) | 2026-04-16 |
| EP3986416A1 (en) | 2022-04-27 |
| BR112022000956A2 (pt) | 2022-04-05 |
| US20220133742A1 (en) | 2022-05-05 |
| US20240261300A1 (en) | 2024-08-08 |
| TW202116324A (zh) | 2021-05-01 |
| JP2022541550A (ja) | 2022-09-26 |
| CA3147891A1 (en) | 2021-01-28 |
| KR20220052927A (ko) | 2022-04-28 |
| EP3986416A4 (en) | 2023-06-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JOP20220008A1 (ar) | مثبطات parp1 | |
| MX2022015272A (es) | Inhibidores de la proteina kras g12c y usos de estos. | |
| ZA202001717B (en) | Compounds, salts thereof and methods for treatment of diseases | |
| BR112022000956A2 (pt) | Métodos de tratamento da hiperplasia adrenal congênita | |
| ECSP18094983A (es) | Derivados de pirazol como inhibidores de la calicreína plasmática | |
| UY35313A (es) | Antiadhesion de leucocitos para mitigar los potenciales eventos adversos causados por los dominios de unión específicos de cd3 | |
| JOP20210140A1 (ar) | معالجة متلازمة الحذف 22q11.2 بكانابيديول | |
| BR112015001419A8 (pt) | composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo | |
| PH12015502549B1 (en) | Heterocyclic derivatives | |
| CO2022000481A2 (es) | Inhibidores de enzimas | |
| CO2021015264A2 (es) | Inhibidores de dihidroorotato deshidrogenasa | |
| EA201591339A1 (ru) | Тиазолкарбоксамиды и пиридинкарбоксамиды, используемые в качестве ингибиторов pim-киназы | |
| CO2017006230A2 (es) | Compuestos de n-((het)arilmetil)-heteroaril-carboxamidas como inhibidores de calicreína plasmática | |
| EA202192122A1 (ru) | Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения | |
| EA201692249A1 (ru) | Ингибиторы фосфатидилинозитол-3-киназы | |
| BR112015026297A2 (pt) | terapia combinada composta por um inibidor tor quinase e um composto de 5-quinazolinona substituído para o tratamento de câncer | |
| BR112015023439A2 (pt) | combinação de tratamentos de câncer utilizando micrornas e inibidores egfr-tki | |
| JOP20200291A1 (ar) | معدلات التعبير عن apol1 | |
| MX2022001933A (es) | Inhibidores de enzimas. | |
| MX2022000811A (es) | Inhibidores de enzimas. | |
| CO2022000266A2 (es) | Inhibidores de enzimas | |
| MX2020001493A (es) | Tratamiento con obinutuzumab nuevo subgrupo de pacientes con nuevo linfoma de celulas b grandes difusas (dlbcl). | |
| EA201591055A1 (ru) | Полипептид растворимого рецептора 3 фактора роста фибробластов (fgr3) для применения с целью предотвращения или лечения нарушений, связанных с замедлением роста скелета | |
| MX2022000545A (es) | Inhibidores de enzimas. | |
| MX2023004881A (es) | Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca. |